While the CLL2-GIVe study evaluated the IVenO combination in patients with untreated CLL exhibiting TP53 aberrancy only, this combination has also been studied for younger patients without TP53-aberrant disease (GAIA/CLL13) [25, 111]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.